CFTR Modulators for the Gastroenterologist

Affiliations

¹ From the Division of Gastroenterology and Nutrition & Harvard Medical School, Boston Children's Hospital, Boston, MA.
² the Division of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Irving Medical Center, New York, NY.

Sabina Sabharwal et al. J Pediatr Gastroenterol Nutr. 2023.

. 2023 Oct 1;77(4):445-447.

doi: 10.1097/MPG.0000000000003904. Epub 2023 Aug 7.

¹ From the Division of Gastroenterology and Nutrition & Harvard Medical School, Boston Children's Hospital, Boston, MA.
² the Division of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Irving Medical Center, New York, NY.

No abstract available

Conflict of interest statement

The authors report no conflicts of interest.

1. Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022;21:456–62.
1. Wilson A, Altman K, Schindler T, Schwarzenberg SJ. Updates in nutrition management of cystic fibrosis in the highly effective modulator era. Clin Chest Med. 2022;43:727–42.
1. Tabori H, Arnold C, Jaudszus A, et al. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS One. 2017;12:e0174463.
1. Moshiree B, Freeman AJ, Vu PT, et al. Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis. J Cyst Fibros. 2022;22:266–74.
1. Stallings VA, Sainath N, Oberle M, Bertolaso C, Schall JI. Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations. J Pediatr. 2018;201:229–237.e4.